The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline ...

It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...

The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.

GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $3.5 billion and $2.0 billion ...

Following this month's FDA approval of Eli Lilly’s amyloid-busting antibody Kisunla (donanemab), the Alzheimer’s disease market is set to grow in earnest—and Lilly is already eyeing a spot at the t | ...

The US Food and Drug Administration approved Donanemab, also called Kisunla. Tuesday's decision put the monoclonal antibody ...

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV ...

Called Donanemab, this treatment from Eli Lilly will be sold under its brand name, Kisunla, and works as an intravenous ...

The Food and Drug Administration (FDA) has approved Kisunla ™ (donanemab-azbt) for the treatment of Alzheimer disease.

The FDA today approved Eli Lilly’s Kisunla™ (donanemab-azbt), a once-monthly treatment for adults with early Alzheimer's ...

Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participants' risk of progressing to the next clinical stage ...